Aethlon Medical Sends HIV-AIDS & Hepatitis-C Treatment Technology to India.

SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced that it will begin shipping its Hemopurifier(TM) treatment technology to India today. The Company stated that today's shipment is the first lot of Hemopurifiers that will be sent to support the HIV and Hepatitis-C human studies that were announced in February.

Aethlon Chairman & CEO, James A. Joyce stated, "The initial shipment of our Hemopurifier treatment technology is a significant milestone for our research team, especially when considering that each Hemopurifier represents new hope for infected individuals that don't have access or are unresponsive to the current standard of care." Once received in India, the initial Hemopurifier lot will undergo required biocompatibility and toxicity testing prior to initiating human studies. Aethlon Chief Scientific Officer, Dr. Richard Tullis added, "Our manufacturing and quality procedures are in place and operating efficiently. We are on track to achieve safety and preliminary efficacy data this summer."

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices to treat HIV/AIDS, Hepatitis-C (HCV), and pathogens that are mass casualty biological warfare candidates. Each treatment application employs the use of a proprietary technology known as the Hemopurifier(TM), which is designed to rapidly reduce the presence of infectious disease and toxins in the body. The Hemopurifier converges the established scientific principals of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. More information on Aethlon Medical and the Hemopurifier technology is available at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.